Romosozumab increases bone mineral density in postmenopausal Chinese women with osteoporosis: A randomised phase three study
Open Access
- 3 June 2026
- journal article
- Published by Elsevier in Journal of Orthopaedic Translation
- Vol. 59, 101135
Abstract
No abstract availableKeywords
Funding Information
- Union Chimique Belge
- UCB
- Amgen (GPP 2022)
This publication has 34 references indexed in Scilit:
- The imminent risk of a fracture—existing worldwide data: a systematic review and meta-analysisOsteoporosis International, 2022
- Prevalence of Osteoporosis and Fracture in ChinaJAMA Network Open, 2021
- Validation of the Surrogate Threshold Effect for Change in Bone Mineral Density as a Surrogate Endpoint for Fracture Outcomes: The FNIH-ASBMR SABRE ProjectJournal of Bone and Mineral Research, 2020
- Romosozumab or alendronate for fracture prevention in East Asian patients: a subanalysis of the phase III, randomized ARCH studyOsteoporosis International, 2020
- The epidemiology of osteoporosis, associated fragility fractures, and management gap in ChinaArchives of Osteoporosis, 2019
- Characteristics of recurrent fracturesOsteoporosis International, 2018
- Imminent risk of fracture after fractureOsteoporosis International, 2016
- Secular trends in hip fracture incidence and recurrenceOsteoporosis International, 2008
- Vertebral Fractures Predict Subsequent FracturesOsteoporosis International, 1999
- Updated Data on Proximal Femur Bone Mineral Levels of US AdultsOsteoporosis International, 1998